Nutex Health Statistics
Total Valuation
Nutex Health has a market cap or net worth of $632.23 million. The enterprise value is $888.86 million.
| Market Cap | 632.23M |
| Enterprise Value | 888.86M |
Important Dates
The next estimated earnings date is Thursday, August 7, 2025, after market close.
| Earnings Date | Aug 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Nutex Health has 5.56 million shares outstanding. The number of shares has increased by 24.00% in one year.
| Current Share Class | 5.56M |
| Shares Outstanding | 5.56M |
| Shares Change (YoY) | +24.00% |
| Shares Change (QoQ) | +5.50% |
| Owned by Insiders (%) | 35.47% |
| Owned by Institutions (%) | 15.13% |
| Float | 3.30M |
Valuation Ratios
The trailing PE ratio is 9.48 and the forward PE ratio is 17.02.
| PE Ratio | 9.48 |
| Forward PE | 17.02 |
| PS Ratio | 0.96 |
| Forward PS | 0.80 |
| PB Ratio | 3.19 |
| P/TBV Ratio | 3.76 |
| P/FCF Ratio | 9.11 |
| P/OCF Ratio | 8.90 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 3.91, with an EV/FCF ratio of 12.80.
| EV / Earnings | 13.23 |
| EV / Sales | 1.42 |
| EV / EBITDA | 3.91 |
| EV / EBIT | 4.26 |
| EV / FCF | 12.80 |
Financial Position
The company has a current ratio of 2.27, with a Debt / Equity ratio of 1.24.
| Current Ratio | 2.27 |
| Quick Ratio | 2.18 |
| Debt / Equity | 1.24 |
| Debt / EBITDA | 1.49 |
| Debt / FCF | 4.92 |
| Interest Coverage | 9.65 |
Financial Efficiency
Return on equity (ROE) is 78.92% and return on invested capital (ROIC) is 26.90%.
| Return on Equity (ROE) | 78.92% |
| Return on Assets (ROA) | 22.34% |
| Return on Invested Capital (ROIC) | 26.90% |
| Return on Capital Employed (ROCE) | 35.61% |
| Revenue Per Employee | $780,356 |
| Profits Per Employee | $83,971 |
| Employee Count | 800 |
| Asset Turnover | 1.07 |
| Inventory Turnover | 98.45 |
Taxes
In the past 12 months, Nutex Health has paid $32.63 million in taxes.
| Income Tax | 32.63M |
| Effective Tax Rate | 18.90% |
Stock Price Statistics
The stock price has increased by +1,634.91% in the last 52 weeks. The beta is 1.98, so Nutex Health's price volatility has been higher than the market average.
| Beta (5Y) | 1.98 |
| 52-Week Price Change | +1,634.91% |
| 50-Day Moving Average | 133.33 |
| 200-Day Moving Average | 71.62 |
| Relative Strength Index (RSI) | 45.36 |
| Average Volume (20 Days) | 293,003 |
Short Selling Information
The latest short interest is 517,544, so 9.32% of the outstanding shares have been sold short.
| Short Interest | 517,544 |
| Short Previous Month | 363,219 |
| Short % of Shares Out | 9.32% |
| Short % of Float | 15.70% |
| Short Ratio (days to cover) | 2.17 |
Income Statement
In the last 12 months, Nutex Health had revenue of $624.28 million and earned $67.18 million in profits. Earnings per share was $12.01.
| Revenue | 624.28M |
| Gross Profit | 324.32M |
| Operating Income | 208.46M |
| Pretax Income | -39.95M |
| Net Income | 67.18M |
| EBITDA | 227.28M |
| EBIT | 208.46M |
| Earnings Per Share (EPS) | $12.01 |
Balance Sheet
The company has $84.73 million in cash and $341.36 million in debt, giving a net cash position of -$256.63 million or -$46.20 per share.
| Cash & Cash Equivalents | 84.73M |
| Total Debt | 341.36M |
| Net Cash | -256.63M |
| Net Cash Per Share | -$46.20 |
| Equity (Book Value) | 274.88M |
| Book Value Per Share | 35.65 |
| Working Capital | 224.95M |
Cash Flow
In the last 12 months, operating cash flow was $71.07 million and capital expenditures -$1.63 million, giving a free cash flow of $69.43 million.
| Operating Cash Flow | 71.07M |
| Capital Expenditures | -1.63M |
| Free Cash Flow | 69.43M |
| FCF Per Share | $12.50 |
Margins
Gross margin is 51.95%, with operating and profit margins of 33.39% and 10.76%.
| Gross Margin | 51.95% |
| Operating Margin | 33.39% |
| Pretax Margin | 27.66% |
| Profit Margin | 10.76% |
| EBITDA Margin | 36.41% |
| EBIT Margin | 33.39% |
| FCF Margin | 11.12% |
Dividends & Yields
Nutex Health does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -24.00% |
| Shareholder Yield | -24.00% |
| Earnings Yield | 10.63% |
| FCF Yield | 10.98% |
Analyst Forecast
The average price target for Nutex Health is $262.50, which is 130.65% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $262.50 |
| Price Target Difference | 130.65% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on July 3, 2024. It was a reverse split with a ratio of 0.1:1.
| Last Split Date | Jul 3, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.1:1 |
Scores
Nutex Health has an Altman Z-Score of 1.61 and a Piotroski F-Score of 8. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.61 |
| Piotroski F-Score | 8 |